Stableford Capital II LLC Raises Stake in DexCom, Inc. (NASDAQ:DXCM)

Stableford Capital II LLC grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 236.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,477 shares of the medical device company’s stock after acquiring an additional 10,874 shares during the quarter. Stableford Capital II LLC’s holdings in DexCom were worth $1,204,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Versant Capital Management Inc acquired a new stake in DexCom during the fourth quarter worth about $25,000. Riverview Trust Co increased its holdings in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in shares of DexCom during the 4th quarter valued at approximately $38,000. RPg Family Wealth Advisory LLC acquired a new position in DexCom in the third quarter valued at approximately $57,000. Finally, Covestor Ltd grew its position in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after acquiring an additional 335 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Citigroup upped their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. JPMorgan Chase & Co. upped their price objective on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Finally, Canaccord Genuity Group lifted their target price on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a report on Monday, December 9th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.29.

DexCom Stock Down 0.9 %

DXCM stock opened at $86.83 on Friday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company’s 50 day moving average price is $80.49 and its 200 day moving average price is $76.67. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a market capitalization of $33.92 billion, a price-to-earnings ratio of 51.99, a PEG ratio of 2.22 and a beta of 1.12.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 42,342 shares of company stock valued at $3,628,069. Insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.